|
|
Med BioGene Inc. (MBI: TSX Venture) is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests.
Med BioGene’s lead product under development is LungExpress Dx™, a test for early-stage non-small-cell lung cancer that analyzes the molecular profile of a patient’s tumour to provide information to assist in tailoring treatment for that specific patient. LungExpress Dx™ is the first and only gene expression-based test for non-small-cell lung cancer shown to predict a patient's benefit from chemotherapy and prognosis for survival.
Med BioGene expects to commercialize LungExpress Dx™ in the United States in the second half of 2009.
VISIT THE MBI WEBSITE
FOLLOW THE HOWARD GROUP COMMENTARY ON MBI
| NEWS |
|
| June 25, 2009 |
Med BioGene Announces Closing of Second Tranche of Private Placement |
| June 5, 2009 |
Med BioGene Announces Closing of First Tranche of Private Placement |
| May 29, 2009 |
Med BioGene Reports Financial Results for the First Quarter of 2009 |
| April 29, 2009 |
Med BioGene Reports Financial Results For 2008 |
| April 22, 2009 |
MedBiogene Announces Private Placement And Lead Order |
| March 18, 2009 |
Med BioGene Expands Collaboration With University Health Network for Novel Gene-Markers Predictive of Chemotherapy Response in Lung Cancer |
| March 16, 2009 |
Med BioGene Appoints Life Sciences Veteran as Chief Financial Officer |
| November 28, 2008 |
Med BioGene Reports Financial Results for the Third Quarter 2008 |
| October 23, 2008 |
Med BioGene Broadens Commercialization Team to Oversee Launch Preparations for LungExpress Dx(TM) Gene Expression Test |
| September 18, 2008 |
Med BioGene Completes Final Tranche of Financing |
| August 7, 2008 |
Med BioGene Completes First Tranche of Financing |
| July 7, 2008 |
Med BioGene Announces Financing |
| June 16, 2008 |
Med BioGene Expands Lymphoma Collaboration; Becomes Founding Corporate Collaborator of Translational Working Group in Hematologic Malignancies |
| May 29, 2008 |
Med BioGene Appoints Diagnostics Industry Veteran Dr. Heiner Dreismann to Board of Directors |
| April 30, 2008 |
Med BioGene Reports Financial Results for 2007 |
| April 23, 2008 |
Med BioGene and University Health Network Collaborate to Commercialize Critical Lung Cancer Prognostic Test |
| April 3, 2008 |
Med BioGene Confirms High Accuracy Rate for LymphExpress Dx(TM) |
| February 19, 2008 |
Med BioGene Appoints Diagnostics Industry Veteran Dennis L. Grimaud to Board of Directors |
| January 23, 2008 |
Letter From CEO Erinn Broshko To Shareholders |
| November 28, 2007 |
Med BioGene Inc. Reports Financial Results for the Third Quarter 2007 |
| October 25, 2007 |
Med BioGene Engages U.S. Consulting Firm to Drive Partnering Efforts |
| September 24, 2007 |
Med BioGene Welcomes Renowned Expert to Lymphoma Collaboration |
| September 12, 2007 |
Med BioGene Appoints Dr. Melanie M. Mahtani as Executive Advisor, Commercial Development |
| July 30, 2007 |
Med BioGene Inc.: Dr. Nathan Yoganathan, President and Chief Scientific Officer, Transitions to Senior Advisory Role; Dr. Bradley Mclean Appointed Chief Scientific Officer |
| June 29, 2007 |
Med BioGene Closes Second And Final Tranche Of Private Placement |
| June 1, 2007 |
Med BioGene Announces Closing Of Private Placement |
| May 30, 2007 |
Med BioGene Inc. Reports Financial Results For The First Quarter 2007 |
| April 30, 2007 |
Med BioGene Inc. Reports Financial Results for 2006 |
| March 27, 2007 |
Med BioGene Announces Private Placement |
| March 19, 2007 |
Med BioGene Announces Collaboration to Develop Genetic Biomarkers for Lymphoma and Leukemia for Use in Diagnosis, Prognosis and Drug Development |
| February 27, 2007 |
Med BioGene Appoints Dr. Richard C. Cook To Its Scientific Advisory Board |
| February 15, 2007 |
Med BioGene Enters Development Phase for Genetic Screening Test for Colorectal Cancer |
| February 15, 2007 |
Med BioGene Engages the Howard Group Inc. to Provide Investor and Financial Relations Services |
|
